PGNY at a glance
Progyny, Inc. (PGNY, SEC CIK 1551306) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on August 7, 2026, an 8-K current report on August 6, 2026 and Form 4 insider filings as recently as September 28, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Progyny, Inc. (PGNY) reported revenue of $1.3 billion (up 10.4% from FY2024) and net income of $58.5 million. Diluted EPS was $0.65.
- As of June 30, 2026, 32 institutional investment managers tracked by SignalX reported holding Progyny, Inc. (PGNY) shares worth $1.3 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Swartz Allison on September 23, 2026 of 3,903 shares at $26.10 per share.
- In the last 90 days, PGNY insiders reported 0 open-market purchases ($0) and 3 open-market sales ($485K) on Form 4, a net sale of $485K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $1.3B
- +10.4% vs prior year
- Insiders · 90 days
- 0 buys · 3 sells
- Net −$485K
- 13F holders
- 32 funds
- $1.3B · +3 vs prior quarter
- Latest 8-K
- Aug 6, 2026
- Item 7.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business model: Fertility benefits solution providing proprietary Smart Cycle treatment bundles with care management and pharmacy benefits add-on
- New emphasis on expanded women's health and family building services including pregnancy/postpartum and menopause, strategic investments but not material revenue yet
- Strategic client diversification: expanded to 555 clients across 40+ industries from only 2 at launch, focusing on larger clients with >2,500 covered lives
- Membership grew to 6.7 million covered lives (3.3% increase YoY), revenue increased 10% to $1.29B with fertility benefits up 14% and pharmacy up 5%
- Noteworthy cost structure improvement: gross margin expanded 190 basis points to 23.6%, driven by efficiencies in care management services delivery
Risk Factors
- No specific, timely regulatory or legal risk identified
- Economic impacts from potential changes in healthcare funding affect Progyny's fertility benefits offerings, no quantification provided
- Operational risk from maintaining employee engagement during fast growth with 856 employees, critical to execution and retention
- Market disruption risk from competitors advancing fertility and family-building technologies impacting demand for Progyny services
- No financial or structural risk detail (e.g., leverage or key person) disclosed in this section
Management Discussion & Analysis
- Key segment: Center of Excellence fertility network, risk of losing providers or higher costs impacting margins
- Specialty pharmacy segment risk: supply disruptions or pricing changes could increase costs and reduce profitability
- Forward risks: regulatory changes, contract termination threats, competitive pressures, and provider consolidation potentially harming growth and margins
AI summary of the PGNY 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Revenue $350.5M, up 5% YoY from $332.9M, driven by fertility benefits revenue up 8% and Progyny Rx up 1%
- Gross margin 25.5% vs 23.7% YoY; operating margin 11.4% vs 7.3%
- Net income $28.1M vs $17.1M; net margin 8.0% vs 5.1%
- Fertility benefits solution best-performing line, revenue up 8% versus Progyny Rx up 1%
- Covered lives 7.19M vs 6.69M; ART cycles 16,998 vs 16,938
Risk Factors
- Newly added guidance risk triggered by August 6, 2026 third-quarter and full-year guidance
- Competitive consolidation risk from fertility-practice acquisitions and larger integrated healthcare systems
- Regulatory risk from potential PBM reform, increased disclosure requirements, and OIG review of benefit administrators
- Cybersecurity risk from targeted attacks against healthcare platforms, vendors, provider clinics, and specialty pharmacies
- Client concentration risk despite over 600 employers, with significant revenue exposure to technology-industry clients
AI summary of the PGNY 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 7.01: Regulation FD Disclosure
- Q2 2026 earnings released for quarter ended June 30, 2026
- Supplemental earnings presentation available through Progyny’s investor relations website
Item EX-99.1: Item EX-99.1
- Q2 revenue $350.5M, up 5.3%; excluding the departed large client, growth accelerated to 11.0%
- Gross margin expanded to 25.5% from 23.7%, while net income rose to $28.1M from $17.1M
Item 5.03: Amendments to Articles of Incorporation or Bylaws
- Stockholders eliminated certain supermajority voting requirements, lowering thresholds for future corporate actions
- Default supermajority requirement for certain business combinations removed, potentially increasing transaction flexibility
Item 5.07: Submission of Matters to a Vote of Security Holders
- 72,003,873 shares represented, equal to 91.92% meeting participation
- Three Class I directors elected through 2029, with votes withheld ranging from 12,534,255 to 15,641,448
Item 8.01: Other Events
- Board authorized up to $200 million in common-stock repurchases, funded through available cash balances
- Buybacks may use open-market transactions and Rule 10b5-1 plans
AI summaries of PGNY 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for PGNY
Don't miss the next PGNY filing
- Alerts as it files. A push when PGNY files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut PGNY, by share count.
- Ask anything. An AI agent that reads every PGNY filing and answers with sources.
PGNY alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Swartz Allison | Sell | Sep 23, 2026 | 3,903 | $26.10 |
| Clapp Geoffrey | F | Sep 17, 2026 | 819 | $27.38 |
| GORDON KEVIN K | F | Sep 10, 2026 | 10,500 | $27.24 |
| GORDON KEVIN K | Sell | Sep 10, 2026 | 11,500 | $27.12 |
| GORDON KEVIN K | M | Sep 10, 2026 | 22,000 | - |
| GORDON KEVIN K | M | Sep 10, 2026 | 22,000 | - |
| GORDON KEVIN K | M | Sep 10, 2026 | 22,000 | $13.00 |
| Livingston Mark S. | F | Sep 4, 2026 | 479 | $26.61 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $1.2B | $1.3B |
| Gross Profit | - | $253.4M | $304.5M |
| Operating Income | - | $67.5M | $85.3M |
| Net Income | - | $54.3M | $58.5M |
| Gross Margin | - | 21.7% | 23.6% |
| Op. Margin | - | 5.8% | 6.6% |
| Net Margin | - | 4.7% | 4.5% |
| Balance Sheet | |||
| Total Assets | $756.6M | $607.1M | $742.4M |
| Equity | - | $422.1M | $516.0M |
| ROE | - | 12.9% | 11.3% |
| Per Share | |||
| EPS | - | $0.57 | $0.65 |
| Cash Flow | |||
| Operating CF | - | $179.1M | $210.2M |
| CapEx | $3.6M | $5.4M | $18.4M |
Source: XBRL data in Progyny, Inc. (PGNY)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate PGNY share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 32 | $1.25B |
| Q1 2026 | 29 | $751.5M |
| Q4 2025 | 28 | $1.18B |
| Q3 2025 | 31 | $1.06B |
| Q2 2025 | 30 | $1.02B |
| Q1 2025 | 25 | $665.9M |
| Q4 2024 | 22 | $325.9M |
| Q3 2024 | 16 | $136.4M |
- FMR LLC (Fidelity)+503.5K (+8%)
- Millennium Management+364.9K (+489%)
- AQR Capital Management+141.1K (+22%)
- Dimensional Fund Advisors+115.2K (+7%)
- Wells Fargo & Co+37.8K (+129%)
- Morgan Stanley−751.7K (-33%)
- Bank of America Corp−592.2K (-50%)
- Prudential Financial−435.6K (-77%)
- BlackRock−398.5K (-3%)
- Renaissance Technologies LLC−387.4K (-48%)
- Citadel Advisors LLC+1.79M
- Bridgewater Associates LP+51.7K
- Mangrove Partners+26.3K
Source: 13F-HR filings on SEC EDGAR (aggregated from 213 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
PGNY filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Sep 28, 2026 | - | - | - |
| 4 | Sep 21, 2026 | - | - | - |
| 4 | Sep 18, 2026 | - | - | - |
| 4 | Sep 14, 2026 | - | - | - |
| 4 | Sep 8, 2026 | - | - | - |
| 4 | Sep 8, 2026 | - | - | - |
| 4 | Sep 8, 2026 | - | - | - |
| 4 | Sep 4, 2026 | - | - | - |
| 4 | Sep 1, 2026 | - | - | - |
| 10-Q | Aug 7, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 4 | Jul 16, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 3, 2026 | - | - | |
| 4 | Jun 3, 2026 | - | - | |
| 4 | Jun 3, 2026 | - | - | |
| 4 | Jun 1, 2026 | - | - | |
| 4 | May 29, 2026 | - | - | |
| 8-K | May 27, 2026 | - | Analysis | |
| 4 | May 26, 2026 | - | - | |
| 4 | May 26, 2026 | - | - | |
| 4 | May 26, 2026 | - | - |
Related Health Care companies
- AGL · agilon health, inc.Services-Misc Health & Allied Services, NEC
- DVA · DaVitaServices-Misc Health & Allied Services, NEC
- VMD · VIEMED HEALTHCARE, INC.Services-Misc Health & Allied Services, NEC
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
PGNY SEC filings: frequently asked questions
Are PGNY insiders buying or selling?
In the last 90 days, Progyny, Inc. (PGNY) officers, directors and 10% owners reported no open-market purchases and 3 open-market sales worth $484,637 by 3 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold PGNY stock?
As of June 30, 2026, the largest Progyny, Inc. (PGNY) holders among the 13F filers tracked by SignalX were BlackRock ($334.4 million), FMR LLC (Fidelity) ($201.9 million), Vanguard Portfolio Management LLC ($144.7 million), Vanguard Capital Management LLC ($92.6 million), State Street Corp ($87.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was PGNY's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Progyny, Inc. (PGNY) reported revenue of $1.3 billion (up 10.4% from FY2024) and net income of $58.5 million. Diluted EPS was $0.65. The figures come from the XBRL data in the 10-K.
What are the main risks in PGNY's latest 10-K?
In the 10-K filed February 27, 2026, Progyny, Inc. (PGNY) flagged: No specific, timely regulatory or legal risk identified. Economic impacts from potential changes in healthcare funding affect Progyny's fertility benefits offerings, no quantification provided. (AI summary of the Risk Factors section.)
What did PGNY report in its latest 8-K?
Progyny, Inc. (PGNY) filed an 8-K on August 6, 2026 reporting Item 7.01 (Regulation FD Disclosure). Q2 2026 earnings released for quarter ended June 30, 2026.
What are the latest PGNY SEC filings?
Progyny, Inc. (PGNY) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on August 7, 2026, an 8-K current report on August 6, 2026 and a Form 4 insider filing on September 28, 2026.
What is PGNY's SEC CIK number?
Progyny, Inc. (PGNY)'s SEC Central Index Key (CIK) is 1551306. EDGAR lists every PGNY filing under that number.
Ask anything about PGNY
The research agent reads PGNY's filings, financials, insider trades and 13F holders, then answers with sources.